Alzheimer’s disease has become one of the top health priorities in the U.S.: More than 5 million Americans currently live with the disease, and that figure will continue to grow.
But there’s no effective treatment, and several clinical trials targeting a single molecule — a protein called beta-amyloid — have proven to be costly failures. Many researchers are starting from scratch in their pursuit to understand the biology of dementia.
About the Author Reprints
